Skip to main content
Complete Olympic Games coverage at your fingertips
Your inside track on the Olympic Games
Enjoy unlimited digital access
$1.99
per week for 24 weeks
Complete Olympic Games coverage at your fingertips
Your inside track onthe Olympics Games
$1.99
per week
for 24 weeks
// //

Astrazeneca Plc ADR NASDAQ: AZN-Q

Today's Change
Volume
Real-Time Last Update Last Sale Cboe BZX Real-Time

More stories below advertisement

Latest Press Releases

Telefonaktiebolaget LM Ericsson (NASDAQ: ERIC) Signs Its Biggest Deal Yet of $8.3 billion with Verizon Communications Inc. (NYSE: VZ)
- WallStreetPR - Wed Jul 28, 7:30AM CDT
WallStreetPR - CMTX
Wed Jul 28, 7:30AM CDT
Dyadic Int'l (DYAI) Inks Deal Toward Potential Access to 40% of the World as Covid Vaccine Continues in Development
- WallStreetPR - Wed Jul 28, 7:30AM CDT
WallStreetPR - CMTX
Wed Jul 28, 7:30AM CDT
BYDUREON BCise (exenatide extended-release) Approved in the US for the Treatment of Type 2 Diabetes in Pediatric Patients Ages 10 Years and Older
- Business Wire - Fri Jul 23, 6:00AM CDT
Business Wire - CMTX
Fri Jul 23, 6:00AM CDT
AstraZeneca's BYDUREON BCise (exenatide extended-release), once-weekly injectable suspension has been approved in the US for the treatment of type 2 diabetes (T2D); to improve glycemic control in pediatric patients (10 to 17 years) as an adjunct to diet and exercise.
Respiratory Syntactical Virus (RSV) Market Size, Share, Trends, Analysis and Forecast 2027
- Market Insight Reports - Thu Jul 22, 8:12AM CDT
Market Insight Reports - CMTX
Thu Jul 22, 8:12AM CDT
The report on Respiratory Syntactical Virus (RSV) provides the clients with a comprehensive analysis of crucial driving factors, consumer behavior, growth trends, product utilization, key player analysis, brand positioning and price patterns. The data on pricing patterns is obtained by analyzing product prices of key players also as emerging market players. Furthermore, Respiratory Syntactical Virus (RSV) market research report provides valuable insights on market overview, market segmentation and strategies for established and emerging players.
Delta Means Beta Testing Alpha Strategies in Biotech (NVAX, MRNA, DYAI, PFE, JNJ, BNTX, AZN, IBB)
- WallStreetPR - Thu Jul 22, 7:07AM CDT
WallStreetPR - CMTX
Thu Jul 22, 7:07AM CDT
Aridis Pharmaceuticals Announces Exclusive License of Suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZeneca
- PR Newswire - PRF - Mon Jul 19, 7:30AM CDT
PR Newswire - PRF - CMTX
Mon Jul 19, 7:30AM CDT
/PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that it has entered into an exclusive, worldwide licensing agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to in-license the late stage monoclonal antibody candidate, suvratoxumab.  
Thinking about trading options or stock in AstraZeneca, NVIDIA, Exxon Mobil, General Electric, or Tesla?
- PR Newswire - PRF - Fri Jul 16, 10:15AM CDT
PR Newswire - PRF - CMTX
Fri Jul 16, 10:15AM CDT
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AZN, NVDA, XOM, GE, and TSLA.
Moderna Set to Join S&P 500
- PR Newswire - PRF - Thu Jul 15, 6:01PM CDT
PR Newswire - PRF - CMTX
Thu Jul 15, 6:01PM CDT
/PRNewswire/ -- Moderna Inc. (NASD:MRNA) will replace Alexion Pharmaceuticals Inc. (NASD:ALXN) in the S&P 500 effective prior to the opening of trading on . AstraZeneca Plc (LSE:AZN; NASD:AZN) is acquiring Alexion Pharmaceuticals in a deal expected to be completed soon pending final closing conditions.
Adult Vaccines Market Size, Share, Trends, Analysis and Forecast 2027
- Market Insight Reports - Mon Jul 12, 4:06AM CDT
Market Insight Reports - CMTX
Mon Jul 12, 4:06AM CDT
The report on Adult Vaccines provides the clients with a comprehensive analysis of crucial driving factors, consumer behavior, growth trends, product utilization, key player analysis, brand positioning and price patterns. The data on pricing patterns is obtained by analyzing product prices of key players also as emerging market players. Furthermore, Adult Vaccines market research report provides valuable insights on market overview, market segmentation and strategies for established and emerging players.
F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors
- Globe Newswire - Thu Jul 8, 7:00AM CDT
Globe Newswire - CMTX
Thu Jul 8, 7:00AM CDT
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) ("F-star" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announced that it has entered into an exclusive licensing agreement with AstraZeneca plc (NASDAQ: AZN) ("AstraZeneca"), under which AstraZeneca will receive global rights to research, develop and commercialize next generation Stimulator of Interferon Genes (STING) inhibitor compounds.

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies